Stephen Dilly

Dr. Dilly, most recently, served as CEO and board member of Aimmune Therapeutics, where he currently serves as an special advisor. Previously, he held executive roles at Genentech, Chiron and SmithKline Beecham, and was associated with the development and launch of several marketed drugs. He currently is board chairman of Cognoa, a pediatric behavoral health company, and board chairmen of DNAtrix, developing virus-driven immunotherapies.

  • March 2020

Added to: ImmunoMolecular Therapeutics Inc. - Woburn, MA

IM Therapeutics is developing personalized medicines for autoimmune diseases, including celiac disease,  by building oral drug therapies.